Log in

NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

$55.24
+0.75 (+1.38 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$54.18
Now: $55.24
$56.54
50-Day Range
$52.20
MA: $56.28
$61.69
52-Week Range
$6.37
Now: $55.24
$65.43
Volume377,049 shs
Average Volume680,654 shs
Market Capitalization$3.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.94
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Read More
ChemoCentryx logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.13 million
Book Value$1.14 per share

Profitability

Net Income$-55,490,000.00
Net Margins-192.93%

Miscellaneous

Employees82
Market Cap$3.42 billion
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$55.24
+0.75 (+1.38 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock been impacted by COVID-19 (Coronavirus)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 33.0% and is now trading at $55.24.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ChemoCentryx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ChemoCentryx
.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for ChemoCentryx
.

How can I listen to ChemoCentryx's earnings call?

ChemoCentryx will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%.
View ChemoCentryx's earnings history
.

What price target have analysts set for CCXI?

9 equities research analysts have issued 12 month target prices for ChemoCentryx's stock. Their forecasts range from $54.00 to $102.00. On average, they anticipate ChemoCentryx's stock price to reach $69.78 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts' price targets for ChemoCentryx
.

Has ChemoCentryx been receiving favorable news coverage?

News headlines about CCXI stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ChemoCentryx earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about ChemoCentryx
.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a decline in short interest in July. As of July 31st, there was short interest totaling 4,960,000 shares, a decline of 6.1% from the July 15th total of 5,280,000 shares. Based on an average daily volume of 718,700 shares, the short-interest ratio is presently 6.9 days. Currently, 9.9% of the company's stock are sold short.
View ChemoCentryx's Current Options Chain
.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.65%), Emerald Mutual Fund Advisers Trust (0.59%), International Biotechnology Trust PLC (0.31%), UBS Group AG (0.23%), Swiss National Bank (0.15%) and Alps Advisors Inc. (0.14%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall.
View institutional ownership trends for ChemoCentryx
.

Which institutional investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Alps Advisors Inc., WINTON GROUP Ltd, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, SG Americas Securities LLC, Trexquant Investment LP, and Genesee Capital Advisors LLC. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx
.

Which institutional investors are buying ChemoCentryx stock?

CCXI stock was bought by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Emerald Mutual Fund Advisers Trust, First Trust Advisors LP, Emerald Advisers LLC, Raymond James Financial Services Advisors Inc., Swiss National Bank, Russell Investments Group Ltd., and Rafferty Asset Management LLC.
View insider buying and selling activity for ChemoCentryx
.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $55.24.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $3.42 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.